EbioMedicine:打破HIV多年治疗误区!疗法虽成功但病毒水平丝毫未减

2015-08-06 佚名 生物谷

发表于国际杂志EbioMedicine上的一篇研究报道中,来自利物浦大学的科学家通过研究发现,尽管HIV患者对疗法反应较好,但HIV仍然可以在患者机体中旺盛地生长。在疗法期间,HIV会在免疫细胞中隐藏,病毒往往会通过将其自身的遗传信息插入到免疫细胞CD4 T淋巴细胞的DNA中来在细胞中繁殖。文章中研究者对进行长达14年连续疗法的HIV患者进行研究,测定了患者机体中CD4细胞中含有的整合HIV的水平

发表于国际杂志EbioMedicine上的一篇研究报道中,来自利物浦大学的科学家通过研究发现,尽管HIV患者对疗法反应较好,但HIV仍然可以在患者机体中旺盛地生长。

在疗法期间,HIV会在免疫细胞中隐藏,病毒往往会通过将其自身的遗传信息插入到免疫细胞CD4 T淋巴细胞的DNA中来在细胞中繁殖。文章中研究者对进行长达14年连续疗法的HIV患者进行研究,测定了患者机体中CD4细胞中含有的整合HIV的水平,同时对比了治疗不同时间段的患者机体HIV的水平变化。

结果研究者发现,丛治疗1年至14年里,整合入CD4淋巴细胞的HIV的水平并未减弱,每当CD4细胞复制产生更多细胞时,HIV就会进行自身的增殖,该过程被认为是HIV的静默复制过程,意味着病毒并不需要进行自我复制,而是产生更多新型的病毒颗粒从而感染更多的CD4淋巴细胞。

给HIV患者施用抗逆转录病毒的疗法会阻断新病毒的产生,并且抑制CD4 T淋巴细胞的感染和死亡以及AIDS的进展。过去30年的HIV抗逆转录病毒疗法对于很多患者而言的确将患者机体的病毒控制在了一定的水平之下,并且可以维持患者长久健康的生活,而且研究者也认为在进行了许多年的成功治疗后,患者的机体就会有效清除病毒。

研究者Anna Maria Geretti教授说道,本文研究则表明,HIV或许一直在以其它方式来逃脱疗法的攻击;我们一直认为HIV非常难以完全抑制,而且HIV会在CD4细胞中隐蔽自己,但我们还是希望随着机体不断更新CD4细胞,隐藏的HIV就会慢慢被干掉,然而让我们震惊的是,整合入CD4细胞中的HIV的水平在患者成功治疗的14年间并没有发生任何降低。

好消息是在患者治疗期间研究者并没有看到患者疾病恶化的表现,但坏消息是,我们一直认为通过增加机体免疫反应来有效治疗HIV感染似乎并不太奏效,因为HIV在患者机体中的水平似乎一直没有发生变化。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
    2015-12-20 linagood
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
    2016-06-08 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
    2016-07-09 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
    2016-02-23 docwu2019
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1997070, encodeId=72bd199e07022, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Sun Dec 20 20:42:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773499, encodeId=aa0c1e73499e2, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jun 08 07:42:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917183, encodeId=9498191e1838a, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 09 21:42:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858619, encodeId=299b18586197b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Feb 23 00:42:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308757, encodeId=7a2a1308e57d8, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577432, encodeId=312a15e743251, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606563, encodeId=e30016065630b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 08 07:42:00 CST 2015, time=2015-08-08, status=1, ipAttribution=)]

相关资讯

Science:为何HIV候选疫苗不能抵御感染?

近日,刊登在国际著名杂志Science上的一项研究报告中,来自杜克大学等处的研究者通过研究揭示了为何艾滋病病毒疫苗试验联盟(HVTN)505临床试验中使用的候选疫苗不能够有效保护机体抵御HIV的感染,尽管其可以潜在诱导机体产生抗HIV的抗体,这种特殊疫苗可以刺激抗体识别HIV及肠道中发现的微生物(部分是机体的微生物组成员)。 研究者表示,这些抗体的出现是因为疫苗会增强机体对肠道微生物存在的抗

Lancet HIV:Grazoprevir加Elbasvir可有效治疗HIV和HCV共感染的患者

丙型肝炎病毒(HCV)感染是HIV-1患者发病和死亡的一个主要原因。C-EDGE CO-INFECTION 研究评估了grazoprevir(MK-5172)加elbasvir(MK-8742)对于同时感染HCV和HIV患者的有效性,安全性和耐受性。    在这个非对照、非随机的3期开放性的单臂研究中,有慢性HCV基因型1,4,6和HIV共感染并且未经过治疗的、有或无

法国儿童再创HIV治疗奇迹:停止治疗12年依然健康

加拿大温哥华举行的国际艾滋病大会今天报道了一件不寻常的事迹:法国儿童艾滋病感染者停止治疗12年后依然健康,该事件的报道旨在帮助那些没有接受抗逆转录病毒(ARV)药物治疗的HIV感染者控制病情,同时给艾滋病疫苗开发商一些启示。1996年,法国一名出生时就被确诊的婴儿艾滋病感染者开始服用抗艾滋病药物。但在6岁时,她父母不顾医生的建议,停止了她的治疗。12年后,这个法国小孩依然健康着,且血液里检测不到艾

歪打正着?抗癌药或可为HIV治疗带来希望

  艾滋病一直令人谈之色变。即使在医学高度发达的今天,医学工作者仍没有找到一种方法治愈这种疾病。此前一段时间,一些包括艾滋病疫苗在内的疗法虽然取得了一定的进展,但距离彻底征服这一疾病仍有很长一段时间的距离。甚至在不久之前,通过早期治疗手段,已经宣称“治愈”的密西西比婴儿,最终仍然出现了病情反复的情况。这其中一个重要原因就是在HIV感染者体内有相当一部分病毒是“潜伏”在细胞内部的

Nature:如何击退HIV病毒?

科学家们已经拥有了很好的武器,可以终结HIV病毒的流行,他们现在只需要为这种武器设计出一个比较好的使用方案就可以了。 在肯尼亚维多利亚湖的岸边,渔民们正在沙滩上铺开他们的渔网,晾晒一天的劳动成果。在岸边还扎了一排帐篷,帐篷里的医护人员也在铺网,不过这可不是渔网,这是一种能够帮助科学家们“打捞”出最能够彻底消灭HIV病毒的科研之网。 这些医护人员的帐篷也是人来人往,络绎不绝,因为附近村子里

NEJM:初始抗逆转录病毒治疗早期无临床症状的HIV感染

来自无症状人类免疫缺陷病毒(HIV)感染的患者(他们的CD4+计数超过了350个细胞/mm3)的随机试验数据缺乏初始抗逆转录病毒治疗的益处和风险。      研究人员随机分配的HIV阳性且CD4+计数超过500细胞/mm3的成人患者立即(立即治疗组),或推迟治疗(直到CD4+计数下降到350细胞/mm3,或直到获得性免疫缺陷综合症(AIDS)或其他状态的发展),即